TXG 10x Genomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TXG

Price (delayed)

$33.53

Market cap

$4.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.17

Enterprise value

$3.85B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 47

10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin ...

Highlights
TXG's EPS has soared by 87% year-on-year and by 51% since the previous quarter
The company's net income has surged by 86% YoY and by 48% QoQ
Sector: Healthcare
Industry: Health Information Services
Website: http://www.10xgenomics.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of TXG

TXG stock price

How has the 10x Genomics stock price performed over time
Intraday
4.26%
1 week
19.79%
1 month
54.87%
1 year
258.99%
YTD
105.58%
QTD
57.94%

Financial performance

How have 10x Genomics's revenue and profit performed over time
Revenue
$638.78M
Gross profit
$444.61M
Operating income
-$38.7M
Net income
-$22.66M
Gross margin
69.6%
Net margin
-3.5%
The company's net income has surged by 86% YoY and by 48% QoQ
10x Genomics's net margin has surged by 86% YoY and by 49% QoQ
TXG's operating income has surged by 78% year-on-year and by 37% since the previous quarter
10x Genomics's operating margin has surged by 78% YoY and by 36% QoQ

Price vs fundamentals

How does TXG's price correlate with its fundamentals

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation
P/E
N/A
P/B
5.26
P/S
6.73
EV/EBIT
N/A
EV/EBITDA
144.31
EV/Sales
6.02
TXG's EPS has soared by 87% year-on-year and by 51% since the previous quarter
The P/B is 110% above the last 4 quarters average of 2.4 but 34% below the 5-year quarterly average of 7.6
TXG's equity is up by 15% year-on-year and by 2.3% since the previous quarter
The stock's price to sales (P/S) is 115% more than its last 4 quarters average of 3.0 but 46% less than its 5-year quarterly average of 11.9
10x Genomics's revenue has increased by 2.3% YoY

Efficiency

How efficient is 10x Genomics business performance
TXG's ROS has soared by 88% year-on-year and by 52% since the previous quarter
TXG's ROA has soared by 87% YoY and by 50% from the previous quarter
The return on invested capital has surged by 87% year-on-year and by 51% since the previous quarter
The ROE has soared by 87% YoY and by 49% from the previous quarter

Dividends

What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time
The company's quick ratio rose by 33% QoQ and by 18% YoY
The current ratio has grown by 32% from the previous quarter and by 10% YoY
10x Genomics's debt is 90% lower than its equity
TXG's equity is up by 15% year-on-year and by 2.3% since the previous quarter
10x Genomics's debt to equity has decreased by 9% QoQ and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.